Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. | Arends et al. Arthritis Research Therapy 2011 13 R94 http content 13 3 R94 RESEARCH ARTICLE Open Access Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis a prospective longitudinal observational cohort study 1 1 23 1 Suzanne Arends Elisabeth Brouwer Eveline van der Veer Henk Groen Martha K Leijsma Pieternella M Houtman4 Tim L Th A Jansen4 Cees GM Kallenberg1 and Anneke Spoorenberg4 Abstract Introduction Identifying ankylosing spondylitis AS patients who are likely to benefit from tumor necrosis factoralpha TNF-a blocking therapy is important especially in view of the costs and potential side effects of these agents. Recently the AS Disease Activity Score ASDAS has been developed to assess both subjective and objective aspects of AS disease activity. However data about the predictive value of the ASDAS with respect to clinical response to TNF-a blocking therapy are lacking. The aim of the present study was to identify baseline predictors of response and discontinuation of TNF-a blocking therapy in AS patients in daily clinical practice. Methods AS outpatients who started TNF-a blocking therapy were included in the Groningen Leeuwarden Ankylosing Spondylitis GLAS study an ongoing prospective longitudinal observational cohort study with followup visits according to a fixed protocol. For the present analysis patients were excluded if they had previously received anti-TNF-a treatment. Predictor analyses of response and treatment discontinuation were performed using logistic and Cox regression models respectively. Results Between November 2004 and April 2010 220 patients started treatment with infliximab n 32 etanercept n 137 or adalimumab n 51 . At three and six months 68 and 63 of patients were Assessments in Ankylosing Spondylitis ASAS 20 responders 49 and 46 ASAS40 responders and 49 and 50 Bath Ankylosing Spondylitis Disease Activity Index BASDAI 50 responders .
